(Q34280580)

1 August 2017

1 reference

title

Management of Candida species infections in critically ill patients (English)

1 reference

1 August 2017

0 references

Candida

1 reference

3

Didier Pittet

1 reference

1 August 2017

Philippe Eggimann

1

1 reference

PubMed ID

14652203

1 August 2017

Jorge Garbino

series ordinal

2

1 reference

1 August 2017

1 December 2003

1 reference

Lancet Infectious Diseases

1 August 2017

1 reference

1 August 2017

3

1 reference

1 August 2017

12

1 reference

1 August 2017

772-785

1 reference

Epidemiology of nosocomial fungal infections, with emphasis on Candida species

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Candidemia: current epidemiologic characteristics and a long-term follow-up of the survivors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

The epidemiology of hematogenous candidiasis caused by different Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Fluconazole and the changing epidemiology of candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Epidemiology of Candida species infections in critically ill non-immunosuppressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Effects of nosocomial candidemia on outcomes of critically ill patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Antifungal agents. Part I. Amphotericin B preparations and flucytosine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

1 reference

7 January 2021

Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

1 reference

7 January 2021

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

1 reference

7 January 2021

Antifungal susceptibility patterns of yeast isolates causing bloodstream infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Flucytosine: correlation between toxicity and pharmacokinetic parameters.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Chemotherapy for the Systemic Mycoses: The Prelude to Ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Oral azole drugs as systemic antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Clinical experience with itraconazole in systemic fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

High-dose therapy with fluconazole > or = 800 mg day-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Treatment of Candida albicans fungaemia with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

High-dose fluconazole therapy in patients with severe fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Hepatosplenic candidiasis: successful treatment with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Treatment of Scedosporium apiospermum brain abscesses with posaconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Clinical efficacy of echinocandin antifungals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Micafungin sodium (FK-463).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

The past, present and future of antimycotic combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Predictors of adverse outcome in cancer patients with candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared with aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Treatment of Candida albicans endocarditis: case report and a review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Vertebral osteomyelitis due to Candida species: case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Venous catheter-associated candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Should vascular catheters be removed from all patients with candidemia? An evidence-based review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Risk factors for death among cancer patients with fungemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Risk factors for death in patients with candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Candidemia in a pediatric population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Should central venous catheters be removed as soon as candidemia is detected in neonates?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Rising Incidence of Candida parapsilosis Fungemia in Patients with Hematologic Malignancies: Clinical Aspects, Predisposing Factors, and Differential Pathogenicity of the Causative Strains

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Indications for therapy for fungemia in postoperative patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Clinical significance of Candida isolated from peritoneum in surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Candida colonization and subsequent infections in critically ill surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Early Candida isolations in febrile patients after abdominal surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Urosepsis in the critical care unit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Candiduria as an early marker of disseminated infection in critically ill surgical patients: the role of fluconazole therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Yeast in the urine: solutions for a budding problem

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Management of asymptomatic candiduria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

The Potential Clinical and Economic Benefits of Silver Alloy Urinary Catheters in Preventing Urinary Tract Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Hydrogel/silver ion-coated urinary catheter reduces nosocomial urinary tract infection rates in intensive care unit patients: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

The Role of Candida sp Isolated From Bronchoscopic Samples in Nonneutropenic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Mortality of hospitalized patients with Candida endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Hematogenous candida endophthalmitis in patients receiving parenteral hyperalimentation fluids

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Endogenous endophthalmitis among patients with candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Prospective study of Candida endophthalmitis in hospitalized patients with candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Retinal lesions in septicemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A Prospective Search for Ocular Lesions in Hospitalized Patients with Significant Bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Infection control in the ICU.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A computer-assisted management program for antibiotics and other antiinfective agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Ketoconazole prevents Candida sepsis in critically ill surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Prophylactic antifungal therapy in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

A Double-Blind, Randomized, Placebo-Controlled Trial of Itraconazole Capsules as Antifungal Prophylaxis for Neutropenic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

The Effect of Prophylactic Fluconazole on the Clinical Spectrum of Fungal Diseases in Bone Marrow Transplant Recipients with Special Attention to Hepatic Candidiasis: An Autopsy Study of 355 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Selective gut decontamination reduces nosocomial infections and length of stay but not mortality or organ failure in surgical intensive care unit patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Candida infection with and without nystatin prophylaxis. A 11-year experience with patients with burn injury

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Fluconazole prophylaxis against fungal colonization and infection in preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Fluconazole improves survival in septic shock: a randomized double-blind prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Role of interleukin-18 in host defense against disseminated Candida albicans infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

New perspectives on the immunology of chronic mucocutaneous candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Immunoblot analysis of the serological response in systemic candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

In vitro inhibition of adhesion of Candida albicans clinical isolates to human buccal epithelial cells by Fuc alpha 1----2Gal beta-bearing complex carbohydrates.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900831-4

7 January 2021

10.1016/S1473-3099(03)00831-4

Identifiers

DOI

1 reference

release_ojpeulr23nc55bkmrv5cgdxb3i

1 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ojpeulr23nc55bkmrv5cgdxb3i

24 November 2022

mapped directly with Wikidata item

PubMed ID

14652203

1 reference

PubMed ID

14652203